Difference between revisions of "Maprotiline-bupropion"
From Psychiatrienet
| (5 intermediate revisions by 3 users not shown) | |||
| Line 3: | Line 3: | ||
| to = bupropion | | to = bupropion | ||
| stop = | | stop = | ||
| − | + | {{stopMaprotiline}} | |
| − | |||
| − | |||
| start = | | start = | ||
| − | * '''Day | + | * '''Day 7:''' simultaneously start administration of bupropion in a dosage of 150 mg/day and continue administration of maprotiline according to the scheme above. |
| − | * '''Day | + | * '''Day 14:''' stop administration of maprotiline and continue administration of bupropion. |
| info = | | info = | ||
| − | * Bupropion is a strong inhibitor of CYP2D6, which metabolizes maprotiline. }} | + | * Bupropion is a strong inhibitor of CYP2D6, which metabolizes maprotiline. |
| + | * {{RiskSeizureBupropionTCA}} | ||
| + | }} | ||
Latest revision as of 16:16, 28 October 2015
| ||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
Switch medication from maprotiline to bupropion.[1] [2]
Stop maprotiline - Before day 1: gradually reduce dosage of maprotiline to a maximum of 75 mg/day.
- Day 1: reduce dosage of maprotiline to 50 mg/day.
- Day 7: reduce dosage of maprotiline to 25 mg/day.
- Day 14: stop dosage of maprotiline.
Start bupropion- Day 7: simultaneously start administration of bupropion in a dosage of 150 mg/day and continue administration of maprotiline according to the scheme above.
- Day 14: stop administration of maprotiline and continue administration of bupropion.
More information- Bupropion is a strong inhibitor of CYP2D6, which metabolizes maprotiline.
- The concomitant use of bupropion and tricyclic antidepressants (TCAs) may potentiate the risk of seizures. These agents are all epileptogenic and may have additive effects on the seizure threshold.
- ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
- ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
